Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC EBITDA Margin

EBITDA as a percentage of revenue.

Embecta Corp.NASDAQ: EMBC

EBITDA Margin · Q2 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 20.2%

EBITDA Margin was 20.2% in Q2 FY2026, down 8.4 pp from a year earlier. On a trailing-twelve-month basis it was 30.9%, up 11.2 pp year over year. Over 3 fiscal years it narrowed by 2.3 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 27.1% for the fiscal year ending Sep 2026, down from 27.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
20.2%-16.5 pp QoQ
Last fiscal yearSep 2025
27.3%+9.6 pp YoY
LTMMar 2026
30.9%+11.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-8.4 pp-15.4 pp-6.9 pp
1 year+9.6 pp-0.1 pp-9.7 pp
3 years-2.3 pp-2.3 pp+0.0 pp
5 years+5.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
27.3%
Year-over-year change
+9.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 EBITDA Margin of 30.9% is the highest of the 11 companies compared; the peer median is -33.5%.
  • Its year-over-year change of +11.2 pp is the 4th highest of 11, against a peer median of -3.8 pp.
  • Over three fiscal years its change of -2.3 pp compares with a peer median of -25.1 pp.
EMBC Competitors Peer median
EBITDA Margin for EMBC and competitors
Company Period LTM level YoY 3-year change
EMBCEmbecta Corp.LTM Mar 202630.9% +11.2 pp-2.3 pp
SIGASIGA Technologies, Inc.LTM Mar 202629.3% -22.9 pp-7.6 pp
EBSEmergent BioSolutions Inc.LTM Mar 202622.8% +10.3 pp+31.0 pp
CDNACareDx, IncLTM Jun 20263.4% +11.1 pp+17.5 pp
EVHEvolent Health, Inc.LTM Mar 2026-16.7% -18.0 pp-22.5 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-26.6% +89.9 pp-148.5 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-102.7% -35.0 pp-65.4 pp
PSNLPersonalis, Inc.LTM Mar 2026-132.6% -47.0 pp—
VIRVir Biotechnology, Inc.LTM Mar 2026-669.6% +2109.2 pp-668.6 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-4732.2% +354.4 pp—
Peer median (excluding EMBC) -33.5%-3.8 pp-25.1 pp

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue1.17B1.13B1.12B1.12B1.08B
Cost of Revenue365M354.6M370.9M394.2M400.9M
Gross Profit800M774.9M749.9M728.9M679.5M
Gross Margin68.7%68.6%66.9%64.9%62.9%
Research & Development63M65M85.2M78.8M21.5M
Selling, General & Admin240.3M294.8M341.3M365.1M331.4M
Operating Expenses308M396.8M520.3M554.7M350.2M
Depreciation & Amortization38M31.7M32.7M42.5M51.1M
EBITDA533M334.5M245.4M199M294.7M
EBITDA Margin45.8%29.6%21.9%17.7%27.3%
Operating Income492M378.1M229.6M174.2M329.3M
Operating Margin42.2%33.5%20.5%15.5%30.5%
Interest Income00000
Interest Expense046.2M107M112.3M107.3M
Other Income / Expenses3M(121.5M)(123.9M)(130M)(193M)
Income Before Tax495M256.6M105.7M44.2M136.3M
Pre-Tax Margin42.5%22.7%9.4%3.9%12.6%
Income Tax Expense80M33M35.3M(34.1M)40.9M
Net Income414.8M223.6M70.4M78.3M95.4M
Net Margin35.6%19.8%6.3%7.0%8.8%
EPS (Basic)7.313.921.231.361.64
EPS (Diluted)7.313.891.221.341.62
Weighted Avg Shares56.8M57.06M57.24M58.43M58.31M
Weighted Avg Shares (Diluted)56.8M57.06M57.76M58.33M58.92M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.